In particular, recent evidence supports the concept that combined BRAF-MEK inhibitors could enhance recognition of melanoma cells by the immune system, thus favoring the activity of immune-checkpoints inhibitors [91]. The gene discussed is MAP2K7; the disease is melanoma.